RVMDW
Revolution Medicines, Inc.
Key Financials
Operating Income
$-1182369000
↓ 71.5%
Revenue
$0
NaN%
Net Income
$-1131301000
↓ 88.5%
Total Assets
$2.4B
↓ 8.0%
Shareholders' Equity
$1.6B
↓ 28.0%
Total Liabilities
$723.2M
↑ 146.7%
Cash & Equivalents
$383.7M
↓ 29.3%
EPS (Diluted)
$-5.95
↓ 66.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| 4 | 4/29/2026 | View on SEC |
| DEFA14A | 4/28/2026 | View on SEC |
| ARS | 4/28/2026 | View on SEC |
| DEF 14A | 4/27/2026 | View on SEC |
| 144 | 4/27/2026 | View on SEC |
| 4 | 4/17/2026 | View on SEC |
| 8-K | 4/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RVMDW |
| Company Name | Revolution Medicines, Inc. |
| CIK | 1628171 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-481-6801 |